Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 29 Mar 2011 |
| Zealand Pharma to host a Capital Market Day and Site Visit | 22 Mar 2011 |
| Zealand Pharma and Pepscan awarded EU grant of EUR 0.9 million for the joint development of novel peptide drugs | 22 Mar 2011 |
| Warrant Programme - New Articles of Association | 24 Feb 2011 |
| Zealand Pharma A/S establishes a warrant programme for the employees of the company | 10 Feb 2011 |